NCT07852221Recruiting
Patient Selection and Long-Term Outcomes of Pace & Ablate Strategy in Atrial Fibrillation
Patient Selection and Long-Term Outcomes in Patients With a Pace & Ablate Strategy for Interventional Rate Control in Symptomatic Permanent Atrial Fibrillation - A Retrospective Multicenter Analysis
Source: ClinicalTrials.gov · Last updated 1 Oct 2026
Brief summary (registry, in English)
Atrioventricular node ablation with permanent pacing (the "pace-and-ablate" strategy) controls ventricular rate in atrial fibrillation that has not responded to drug therapy or catheter ablation. Chronic right ventricular pacing, however, can cause pacing-induced cardiomyopathy (PICM), and it is not well established which patients are at risk and should therefore receive conduction system pacing or biventricular pacing instead. REPACE is a multicentre retrospective cohort of consecutive patients who underwent atrioventricular node ablation from January 2011 onwards at five centres in Switzerland, the United Kingdom and Poland: Liverpool Heart and Chest Hospital, Inselspital Bern, University Hospital Basel, Geneva University Hospitals and the Silesian Centre for Heart Diseases, Zabrze. More than 2,000 patients ablated up to March 2024 have been included to date; patients ablated after that date at the participating centres are being added. The study has three aims: to validate, in an independent multicentre population, a previously published risk model for pacing-induced cardiomyopathy; to describe the procedural technique and outcomes of atrioventricular node ablation across different health systems; and to estimate the health-economic impact of the pace-and-ablate strategy. Pacing-induced cardiomyopathy is defined as an absolute reduction in left ventricular ejection fraction of at least 10 percentage points to a value below 50%. All potential endpoints are adjudicated by a clinical events committee blinded to the classification made at the site.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2600 (estimated)
- First submitted
- 8 Sept 2026
- Start date
- 5 Jan 2011
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Diseases
- Heart failure, Atrial fibrillation
- NCT number
- NCT07852221
What you commit to
- Study type: Observational
- Planned participants: 2600
- From 5 Jan 2011 to the primary completion date, 30 Jun 2027
- 5 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Note: cardiac resynchronisation therapy or conduction system pacing at baseline is not an eligibility exclusion. Such patients are included in the cohort and in the procedural and health-economic analyses, but are excluded from the validation of the pacing-induced cardiomyopathy risk model, in which a decline in left ventricular function would represent non-response to resynchronisation. No lower limit of baseline ejection fraction is applied.
Other
- \* Documented refusal of the further use of health-related data
Who the study is looking for
- Age 18 years or older at the time of atrioventricular node ablation
- Atrial fibrillation, undergoing atrioventricular node ablation with a permanent cardiac implantable electronic device already in situ or implanted as part of the pace-and-ablate strategy
- Availability of baseline echocardiographic data, including left ventricular ejection fraction
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Basel Coordinator of this site? Confirm its status | Basel | Switzerland | Recruiting |
| Inselspital Universitätsspital Bern Coordinator of this site? Confirm its status | Bern | Switzerland | Recruiting |
| Geneva University Hospitals Coordinator of this site? Confirm its status | Geneva | Switzerland | Recruiting |
| Liverpool Heart and Chest Hospital Coordinator of this site? Confirm its status | Liverpool | United Kingdom | Recruiting |
| Silesian Centre for Heart Diseases Coordinator of this site? Confirm its status | Zabrze | Poland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.